GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

mogamulizumab   Click here for help

GtoPdb Ligand ID: 6477

Synonyms: KW-0761 | mogamulizumab-kpkc | Poteligeo®
Approved drug Immunopharmacology Ligand
mogamulizumab is an approved drug (PMDA (Japan, 2012), EMA & FDA (2018))
Compound class: Antibody
Comment: Mogamulizumab (KW-0761) is a CCR4-targeting mAb with enhanced antibody-dependent cellular cytotoxicity (ADCC) function. It is the only GPCR-targeting mAb on the market (in July 2017).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Bioactivity Comments
Peptide sequence analysis of the heavy chain variable region of mogamulizumab matches sequence ID 9 from patent US7504104 [4], linking this antibody with clones Gal1LV1, Gal1LV2 or Gal1LV3. A graph of CCR4 binding by these antibody clones is provided in the patent, but no affinity value is specified.
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CCR4 Primary target of this compound Hs Antibody Inhibition - - - 1,4
⤷ [1,4]
Ligand mentioned in the following text fields
Chemokine receptors comments